Novartis AG is seeking to raise debt to help fund its $12 billion acquisition of Avidity Biosciences Inc, adding to a flurry of M&A financing deals.
A unit of the Swiss drugmaker is marketing investment-grade US dollar bonds in eight tranches, with maturities ranging from three to 30 years, the company said in a filing. Proceeds from the sale will be used to repay a Feb. 26 bridge loan used to finance the acquisition, according to the document.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.